Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) CEO Nadim Ahmed sold 12,529 shares of Cullinan Therapeutics stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total transaction of $106,872.37. Following the sale, the chief executive officer now owns 430,621 shares in the company, valued at approximately $3,673,197.13. This represents a 2.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Nadim Ahmed also recently made the following trade(s):
- On Tuesday, December 24th, Nadim Ahmed sold 8,400 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $11.87, for a total transaction of $99,708.00.
Cullinan Therapeutics Stock Down 5.8 %
Cullinan Therapeutics stock traded down $0.49 during mid-day trading on Monday, hitting $8.00. The company's stock had a trading volume of 264,245 shares, compared to its average volume of 461,124. Cullinan Therapeutics, Inc. has a twelve month low of $8.14 and a twelve month high of $30.19. The stock's fifty day moving average price is $10.53 and its two-hundred day moving average price is $13.91. The stock has a market capitalization of $465.88 million, a P/E ratio of -2.81 and a beta of -0.16.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.02. Equities analysts expect that Cullinan Therapeutics, Inc. will post -3.04 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Cullinan Therapeutics in a research note on Friday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $32.50.
Get Our Latest Stock Analysis on Cullinan Therapeutics
Institutional Trading of Cullinan Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Amalgamated Bank boosted its holdings in shares of Cullinan Therapeutics by 97.3% in the third quarter. Amalgamated Bank now owns 1,768 shares of the company's stock worth $30,000 after buying an additional 872 shares during the period. Federated Hermes Inc. grew its position in Cullinan Therapeutics by 67.0% during the 4th quarter. Federated Hermes Inc. now owns 3,802 shares of the company's stock worth $46,000 after purchasing an additional 1,525 shares in the last quarter. Virtus ETF Advisers LLC grew its position in Cullinan Therapeutics by 37.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,828 shares of the company's stock worth $71,000 after purchasing an additional 1,600 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in Cullinan Therapeutics during the 4th quarter valued at $77,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Cullinan Therapeutics in the fourth quarter valued at $83,000. Institutional investors and hedge funds own 86.31% of the company's stock.
About Cullinan Therapeutics
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Further Reading
Before you consider Cullinan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.
While Cullinan Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
